FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548444705> ?p ?o ?g. }

• W2548444705 abstract "Abstract Bortezomib alone or in combination with chemotherapeutic agents produce a rapid disease control in patients with multiple myeloma (MM). However, laboratory factors predictive of outcome with bortezomib remain obscure. The aim of this study is to determine whether serum free light chain (SFLC) measurements could be a new sensitive test for the early detection of response to treatment with bortezomib and to perform an analysis of biochemical markers to determine their value in predicting response. Data from evaluable 49 patients receiving 2–7 cycles (median, 4) of bortezomib were analyzed. During the first and second cycles of bortezomib treatment, serial serum samples were prospectively collected for simultaneous measurement of SFLC, intact immunoglobulin (Ig) and biochemical markers such as lactic dehydrogenase (LDH), alkaline phosphatase (ALP), uric acid, calcium and phosphorus. SFLC and Ig were measured on day 0 and 12 each cycle and the biochemical markers on day 0, 2, 5, 9 and 12. Twenty-seven patients, 10, 1, 1 and 8 were IgG, IgA, IgM, IgD myelomas and light chain disease (LCD), respectively. Two patients did not secrete monoclonal protein. Patients received bortezomib alone (n=25) 1.0–1.3 mg/m2 for 3–4 week cycles along with various combinations including dexamethasone, thalidomide and/or doxorubicin (n=24). Forty of 49 patients (81.6%) showed an objective response (CR+PR) response upon completion of bortezomib treatment while 9 patients had &lt;PR by EBMT criteria according to monoclonal Ig concentration. Thirty-two of 39 patients (82.1%) with intact Ig MM patients had an abnormal SFLC concentration kinetics after the second bortezomib treatment. All 8 patients with LCD and 2 patients with non-secretory MM showed elevated concentrations of one or both SFLC. In comparison to the intact Ig levels, SFLC concentrations fell more rapidly in response to bortezomib treatment and the pattern of initial SFLC response seems to be an early indication of tumor response or resistance (see the figure; the response after the second cycle was assessed by concentrations of intact Ig or SFLC, respectively). The increase of LDH levels from baseline between two groups during and upon completion of two cycles of therapy was statistically significant (P=0.001). The increase of UA levels from baseline exhibited a marginal significance (P=0.081). In addition, we observed significantly higher mean ALP elevation in the responder group compared with the non-responder group during the two cycles (P=0.027). The monitoring of SFLC provides a unique opportunity to follow the kinetics of tumor kill especially when the monoclonal Ig was not detected. In addition, changes in SFLC concentrations can be used as an early biomarker to assess a rapid response to bortezomib treatment. Biochemical marker assays showed that the response to bortezomib might be associated with tumor lysis and/or osteoblastic activation. Response to bortezomib treatment Response to bortezomib treatment" @default.
• W2548444705 created "2016-11-11" @default.
• W2548444705 creator A5009770843 @default.
• W2548444705 creator A5019604231 @default.
• W2548444705 creator A5021499196 @default.
• W2548444705 creator A5034751203 @default.
• W2548444705 creator A5036020306 @default.
• W2548444705 creator A5043846826 @default.
• W2548444705 creator A5043910009 @default.
• W2548444705 creator A5044372572 @default.
• W2548444705 creator A5050292329 @default.
• W2548444705 creator A5057482418 @default.
• W2548444705 creator A5086500437 @default.
• W2548444705 date "2006-11-16" @default.
• W2548444705 modified "2023-10-09" @default.
• W2548444705 title "Changes in Serum Free Light Chain and Biochemical Markers in Patients with Multiple Myeloma Receiving Bortezomib Treatment." @default.
• W2548444705 doi "https://doi.org/10.1182/blood.v108.11.5028.5028" @default.
• W2548444705 hasPublicationYear "2006" @default.
• W2548444705 type Work @default.
• W2548444705 sameAs 2548444705 @default.
• W2548444705 citedByCount "0" @default.
• W2548444705 crossrefType "journal-article" @default.
• W2548444705 hasAuthorship W2548444705A5009770843 @default.
• W2548444705 hasAuthorship W2548444705A5019604231 @default.
• W2548444705 hasAuthorship W2548444705A5021499196 @default.
• W2548444705 hasAuthorship W2548444705A5034751203 @default.
• W2548444705 hasAuthorship W2548444705A5036020306 @default.
• W2548444705 hasAuthorship W2548444705A5043846826 @default.
• W2548444705 hasAuthorship W2548444705A5043910009 @default.
• W2548444705 hasAuthorship W2548444705A5044372572 @default.
• W2548444705 hasAuthorship W2548444705A5050292329 @default.
• W2548444705 hasAuthorship W2548444705A5057482418 @default.
• W2548444705 hasAuthorship W2548444705A5086500437 @default.
• W2548444705 hasConcept C126322002 @default.
• W2548444705 hasConcept C143998085 @default.
• W2548444705 hasConcept C159654299 @default.
• W2548444705 hasConcept C203014093 @default.
• W2548444705 hasConcept C2776364478 @default.
• W2548444705 hasConcept C2777478702 @default.
• W2548444705 hasConcept C2779609412 @default.
• W2548444705 hasConcept C2780401358 @default.
• W2548444705 hasConcept C36394416 @default.
• W2548444705 hasConcept C71924100 @default.
• W2548444705 hasConcept C90924648 @default.
• W2548444705 hasConceptScore W2548444705C126322002 @default.
• W2548444705 hasConceptScore W2548444705C143998085 @default.
• W2548444705 hasConceptScore W2548444705C159654299 @default.
• W2548444705 hasConceptScore W2548444705C203014093 @default.
• W2548444705 hasConceptScore W2548444705C2776364478 @default.
• W2548444705 hasConceptScore W2548444705C2777478702 @default.
• W2548444705 hasConceptScore W2548444705C2779609412 @default.
• W2548444705 hasConceptScore W2548444705C2780401358 @default.
• W2548444705 hasConceptScore W2548444705C36394416 @default.
• W2548444705 hasConceptScore W2548444705C71924100 @default.
• W2548444705 hasConceptScore W2548444705C90924648 @default.
• W2548444705 hasLocation W25484447051 @default.
• W2548444705 hasOpenAccess W2548444705 @default.
• W2548444705 hasPrimaryLocation W25484447051 @default.
• W2548444705 hasRelatedWork W1984769032 @default.
• W2548444705 hasRelatedWork W2044351324 @default.
• W2548444705 hasRelatedWork W2330049167 @default.
• W2548444705 hasRelatedWork W2569927015 @default.
• W2548444705 hasRelatedWork W2892265035 @default.
• W2548444705 hasRelatedWork W3158645379 @default.
• W2548444705 hasRelatedWork W4229333964 @default.
• W2548444705 hasRelatedWork W4294719323 @default.
• W2548444705 hasRelatedWork W3031758735 @default.
• W2548444705 hasRelatedWork W3032664604 @default.
• W2548444705 isParatext "false" @default.
• W2548444705 isRetracted "false" @default.
• W2548444705 magId "2548444705" @default.
• W2548444705 workType "article" @default.